SCHEMBL4606870

SCHEMBL4606870

C=C/C=C\[CH]C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL834242 1.00
SCHEMBL161162 1.00
SCHEMBL3764002 0.96
SCHEMBL581266 0.76
SCHEMBL581267 0.76
SCHEMBL316478 0.76
SCHEMBL851233 0.76
SCHEMBL130885 0.76
SCHEMBL25023638 0.72 ALDH1A1 (0.44)
SCHEMBL611581 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734209-B2 MACROCYCLIC LACTONES HAVING ANTI-CANCER ACTIVITY AND VACUOLAR ATPASE INHIBITORY ACTIVITY BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM 2004-05-11 US claimed
US-20040063778-A1 Synthetic salicylihalamides, apicularens and derivatives thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-04-01 US claimed
US-6617348-B1 Treating or preventing osteoporosis UT SOUTHWESTERN MEDICAL CENTER 2003-09-09 US claimed
EP-1307439-A2 SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF Board of Regents, The University of Texas System (US) 2003-05-07 EP claimed
WO-2002012223-A2 SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-02-14 WO claimed
EP-1944307-A2 Synthetic Salicylihalamides, Apicularens and Derivatives Thereof Board of Regents, The University of Texas System (US) 2008-07-16 EP disclosed
US-20060116390-A1 Hepatitis c virus inhibitors LG LIFE SCIENCES LTD. (KR) 2006-06-01 US disclosed
EP-1633725-A1 HEPATITIS C VIRUS INHIBITORS LG Life Sciences Ltd. (KR) 2006-03-15 EP disclosed
US-6936723-B2 Synthetic salicylihalamides, apicularens and derivatives thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2005-08-30 US disclosed
WO-2004111013-A1 HEPATITIS C VIRUS INHIBITORS LG LIFE SCIENCES LTD. (KR) 2004-12-23 WO disclosed
US-20040171672-A1 Synthetic salicylihalamides, apicularens and derivatives thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-02 US disclosed
US-6734209-B2 MACROCYCLIC LACTONES HAVING ANTI-CANCER ACTIVITY AND VACUOLAR ATPASE INHIBITORY ACTIVITY BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM 2004-05-11 US disclosed
WO-2002012223-A2 SYNTHETIC SALICYLIHALAMIDES, APICULARENS AND DERIVATIVES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-02-14 WO disclosed
EP-0863866-B1 BUTYRATE PRODRUGS OF LACTIC ACID VERTEX PHARMA (US) 2001-05-02 EP disclosed
US-6225350-B1 ADMINISTERING BUTYRATE PRODRUG FOR THERAPY OF CYSTIC FIBROSIS VERTEX PHARMACEUTICALS, INC. 2001-05-01 US disclosed
US-5912269-A SICKLE CELL SYNDROME, ANTICARCIOGENIC AGENTS VERTEX PHARMACEUTICALS, INC. (US) 1999-06-15 US disclosed
US-5883123-A GAMMA GLOBIN AND FETAL HEMOGLOBIN, SICKLE CELL SYNDROME AND THALASSEMIA SYNDROME VERTEX PHARMACEUTICALS, INC. (US) 1999-03-16 US disclosed
US-5880152-A INFLAMMATORY BOWEL DISEASE VERTEX PHARMACEUTICALS, INC. (US) 1999-03-09 US disclosed
EP-0863866-A1 BUTYRATE PRODRUGS OF LACTIC ACID Vertex Pharmaceuticals Incorporated (US) 1998-09-16 EP disclosed
WO-1997012855-A1 BUTYRATE PRODRUGS OF LACTIC ACID VERTEX PHARMACEUTICALS INCORPORATED (US) 1997-04-10 WO disclosed